CD47 and neoplasm: However, experimental administration of monoclonal antibodies or soluble SIRPα (Fc-fusion) that bind CD47 and block the CD47-SIRPα signaling pathway promotes tumor cell phagocytosis, inhibits tumor growth in mice, and increases survival [92, 95].